Page 102 - CL Armchair Case

However, events were beginning to move against Shkreli

"As early as next week, the Board should remove Martin as

CEO. ... the price drop has to be significant and tied to

something. ... This cannot be seen as something that

appears to be as arbitrary as the price hike in the first

place." — Outside PR consultant, Oct. 8. (4)

Moreover, earlier in the month, New York Attorney General

Eric Schneiderman's antitrust bureau said it was

investigating Turing Pharamaceuticals over concerns that

the company might be 'unlawfully' restraining competition.

It was thought that Turing was reportedly doing this by

distributing Daraprim through a limited number of specialty

pharmacies in order to prevent generic manufacturers from

obtaining access to samples to make their own version.